End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.
The aim of the non-interventional study is to document efficacy and tolerability of rasagiline as a combination therapy in patients with wearing-off-/End-of-dose fluctuations and the effect of rasagiline on individual wearing-off symptoms, recognized by wearing-off questionnaire 32 (WOQ-32).
Study Type
OBSERVATIONAL
Enrollment
261
AZILECT® 1mg Tablets
Wearing-off Questionnaire-32 (WOQ-32)
Alterations of 32 different wearing-off symptoms (Patient questionnaire)
Time frame: 12 weeks
WHO-5
Alterations of patient's Quality of life (patient questionnaire)
Time frame: 12 weeks
GI-I
Self-Assessment of global improvement (patient questionnaire)
Time frame: 12 weeks
Columbia University Rating Scale (CURS)
Alteration of PD symptoms (physician rated questionnaires)
Time frame: 12 weeks
Clinical global impression improvement (CGI-I)
(physician rated questionnaires)
Time frame: 12 weeks
Percentage of participants with adverse events
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Teva Investigational Sites
Aalen, Germany
Teva Investigational Sites
Achim, Germany
Teva Investigational Sites
Altenburg, Germany
Teva Investigational Sites
Altenholz, Germany
Teva Investigational Sites
Alzenau in Unterfranken, Germany
Teva Investigational Sites
Apolda, Germany
Teva Investigational Sites
Aschaffenburg, Germany
Teva Investigational Sites
Bad Honnef, Germany
Teva Investigational Sites
Bad Kissingen, Germany
Teva Investigational Sites
Bad Mergentheim, Germany
...and 130 more locations